Catenacci, D., Tebbutt, N.C., Davidenko, I., Murad, A.M., Al-Batran, S.E., Ilson, D.H., et al. (2017) Ril-Otumumab plus Epirubicin, Cisplatin, and Capecitabine as First-Line Therapy in Advanced MET-Positive Gastric or Gastro-Oesophageal Junction Cancer (RILOMET-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1467-1482.
https://doi.org/10.1016/S1470-2045(17)30566-1

has been cited by the following article:

• TITLE: Research Progress in Targeted Therapy for Esophageal Cancer

  AUTHORS: Jinming Hu, Yanhua Xu

  KEYWORDS: Immunotherapy, Targeted Therapy, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.5, May 16, 2024

  ABSTRACT: Esophageal cancer (EC) is a prevalent malignant tumor that affects the digestive system and is often linked to a poor prognosis. The absence of effective early screening methods results in the diagnosis of esophageal cancer (EC) patients at advanced or metastatic stages. While historically considered incurable, ongoing advancements in medical research have led to the integration of various treatment modalities as primary approaches for managing advanced endometrial cancer. These modalities include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Notably, the introduction of targeted therapy and immunotherapy has significantly enhanced the survival rates of individuals with EC. Immunotherapy has appeared as the predominant treatment for advanced esophageal cancer, while targeted therapy faces certain obstacles. Consequently, this review primarily focuses on the advancements in targeted therapy for esophageal cancer (EC), evaluating the effectiveness and safety of relevant medications, and aiming to provide guidance for the comprehensive management of EC based on current research findings.